<table border="1"><tr><th>Creation</th><td><ul><li>2001</li></ul></td></tr><tr><th>Key characters</th><td><ul><li>R. David Yost, CEO &amp; Director | Michael DiCandilo, CFO</li></ul></td></tr><tr><th>Legal form</th><td><ul><li>Société par share</li></ul></td></tr><tr><th>Action</th><td><ul><li>New York Stock Exchange (ABC)</li></ul></td></tr><tr><th>Head Office</th><td><ul><li>Chesterbrook, Pennsylvania | United States</li></ul></td></tr><tr><th>Direction</th><td><ul><li>Steven Collis (since 2016)</li></ul></td></tr><tr><th>Activity</th><td><ul><li>Pharmaceutical Industry</li></ul></td></tr><tr><th>Products</th><td><ul><li>Medication</li></ul></td></tr><tr><th>Staff</th><td><ul><li>approximately 21,000 (2018)</li></ul></td></tr><tr><th>Website</th><td><ul><li>www.amerisourcebergen.net</li></ul></td></tr><tr><th>Capitalization</th><td><ul><li>USD 18,097 million (October 2019)</li></ul></td></tr><tr><th>Turnover</th><td><ul><li>167 940 million USD (2018)</li></ul></td></tr><tr><th>Net income</th><td><ul><li>$1,658 million (2018)</li></ul></td></tr></table>